// App-Quantinova.ai

5047 : A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Eric Jay Small

Principal Investigators

  • Raymond S. Lance

  • Charles H. Redfern

  • Nadeem A. Sheikh

  • Neal D. Shore

  • Frederick E. Millard

  • Thomas A. Gardner

  • Lawrence Ivan Karsh

  • Nancy Ann Dawson

  • Candice McCoy

  • Andrew Stubbs

  • Todd DeVries

  • Corazon P. dela Rosa

Medical Centers

  • The Urology Center of Colorado, Denver, CO

  • Urology Indiana University Health, Indianapolis, IN

  • Dendreon Corporation, Seattle, WA

  • Georgetown University Medical Center, Washington, DC

  • University of California, San Francisco, San Francisco, CA

  • Sharp Clinical Oncology Research, San Diego, CA

  • Eastern Virginia Medical School, Norfolk, VA

  • Moores Cancer Center, San Diego, CA

  • Carolina Urologic Research Center, Myrtle Beach, SC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Adenomatous Polyposis Coli

  • Intercellular adhesion molecule 1

  • Tenascin-C

Drug/Treatment

  • CB-7598

  • Sipuleucel-T

  • Prednisone

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • NCT01487863

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved